

# Role of Microbiome, Infection, and Inflammation in Autoimmune Diseases

## Authors:

**Negin Amini**

Islamic Azad University Shahrekord Branch

**Maryam Azimzadeh**

Khomein University of Medical Sciences

**Maryam Delavari Dosar**

Islamic Azad University East Tehran Branch

**Atousa Moghadam Fard**

ERIS Research Institute

**Niloofer Habibzadeh**

Yazd shahid Sadoughi University of Medical Sciences

**Sana Yahyazadehjasour**

University of Tehran

**Erfan Rahmani**

Tehran University of Medical Sciences

**Roozbeh Roohinezhad**

Iran University of Medical Sciences

**Fatemeh Farrokh**

Shahid Beheshti University of Medical Sciences

**Yalda Ghasemi**

Shahid Ashrafi Esfahani University

**Hajar Yousofi**

Islamic Azad University, Tehran Medical Branch

**Zahra Salim Khanian**

Azad University

**Fatemeh Taheri**

Islamic Azad University Pharmaceutical Sciences Branch

**Mehrdad Farrokhi**

ERIS Research Institute



## **Book Details:**

**Publisher: Kindle**

**Publication Date: March 2023**

**Language: English**

**Dimensions: 5 x 0.39 x 8 inches**



# Contents

## Chapters

- 1- Pathophysiology of Multiple Sclerosis
- 2- Role of Microbiome, Infection, and Inflammation in Multiple Sclerosis
- 3- Pathophysiology of Oral Lichen Planus
- 4- Role of Microbiome, Infection, and Inflammation in Oral Lichen Planus
- 5- Pathophysiology of Psoriasis
- 6- Role of Microbiome, Infection, and Inflammation in Psoriasis
- 7- Pathophysiology of Rheumatoid Arthritis
- 8- Role of Microbiome, Infection, and Inflammation in Rheumatoid Arthritis
- 9- Pathophysiology of Crohn's Disease
- 10- Role of Microbiome, Infection, and Inflammation in Crohn's Disease
- 11- Role of Microbiome, Infection, and Inflammation in Other Autoimmune Diseases



## 1-Pathophysiology of Multiple Sclerosis

### *Multiple sclerosis(MS)*

Multiple sclerosis(MS) is a complex and poorly known disorder, where many of the fundamental questions relating to etiology and susceptibility remain unanswered. It affects cases in their early adult life, and has a huge effect functionally, financially and in terms of quality of life. Costs are considerable and rise steadily with increasing severity of the disease. The last two decades have shown developments in our understanding and treatment of MS, but there are two facts that stand out above all others. The first is the development in the number of disease-modifying treatments (DMTs) available for relapsing-remitting MS(RRMS), in contrast to the paucity of effective managements for the progressive types of the condition, coupled with the lack of a major impact of DMTs on relapse-unrelated disability. The second development is the greater focus on active treatment, with the case at the center. The emergence of effective managements has created an impetus to diagnose as early as possible and encourage treatments at the earliest point in time. This is particularly apposite given the emerging evidence for activity prior to any overt clinical presentations. These developments may have role in the improved longevity in MS, and improved rates of worsening and evolution to secondary-progressive MS (SPMS) in comparison to earlier natural history cohorts. The plethora of new agents also poses challenges in indicating the right agent for the right case at the right time and the era of personalized

# You Can Buy the Full Version of This Book via the Provided Link:

[Amazon Link](#)

## Product details:

- ASIN : B0BZ31ZRC4
- Publisher : Kindle (March 20, 2023)
- Language : English
- Paperback : 102 pages
- ISBN-13 : 979-8387809347
- Item Weight : 5.9 ounces
- Dimensions : 5 x 0.23 x 8 inches